We are partnering with the Friedrich Miescher Institute on more than 50 research projects to improve and extend people’s lives.

From January 21-24 2020, Novartis attended the World Economic Forum Annual Meeting in Davos, Switzerland.

Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world.

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.

Volunteerism and giving back to communities where we live and work are more than just tradition; they’re core values.